Abnormal microRNA expression in Ts65Dn hippocampus and whole blood: Contributions to down syndrome phenotypes

Developmental Neuroscience

Volumn 33, Issue 5, 2011, Pages 451-467

  Keck Wherley, Jennifer ^a,b   Grover, Deepak ^b   Bhattacharyya, Sharmistha ^c   Xu, Xiufen ^b   Holman, Derek ^b   Lombardini, Eric D ^d   Verma, Ranjana ^b   Biswas, Roopa ^c,e   Galdzicki, Zygmunt ^b,e  

^a Departments of Pediatrics   (United States)

^b School of Medicine   (United States)

^c Graduate School of Nursing   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Blood; Creb1; Ezh2; Lung; Mecp2; miR 155; miR 214; miR 223; miR 802; Ship1

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 155; MICRORNA 802; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; RNA PRECURSOR; SHIP1 ENZYME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD; CELL CYCLE; CHROMOSOME 16; CONTROLLED STUDY; DOWN SYNDROME; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GLIA; HIPPOCAMPUS; HISTOPATHOLOGY; LUNG PARENCHYMA; MALE; MOUSE; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; RNA ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; DOWN SYNDROME; GENE EXPRESSION PROFILING; HIPPOCAMPUS; HUMANS; MICE; MICRORNAS; PARIETAL LOBE; PHENOTYPE; TRISOMY;

EID: 83055180664     PISSN: 03785866     EISSN: 14219859     Source Type: Journal    
DOI: 10.1159/000330884     Document Type: Article

References (142)

1. Lejeune JTRGM: Le mogolisme, premier exemple d'aberration autosomique humanie. Ann Génét 1959; 1: 41-49.
2. Korenberg JR, Kawashima H, Pulst SM, Ikeuchi T, Ogasawara N, Yamamoto K, Schonberg SA, West R, Allen L, Magenis E, et al: Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype. Am J Hum Genet 1990; 47: 236-246.
3. Sherman SL, Petersen MB, Freeman SB, Hersey J, Pettay D, Taft L, Frantzen M, Mikkelsen M, Hassold TJ: Non-disjunction of chromosome 21 in maternal meiosis. I. Evidence for a maternal age-dependent mechanism involving reduced recombination. Hum Mol Genet 1994; 3: 1529-1535.
4. Leoncini E, Botto LD, Cocchi G, Anneren G, Bower C, Halliday J, Amar E, Bakker MK, Bianca S, Canessa Tapia MA, Castilla EE, Csaky-Szunyogh M, Dastgiri S, Feldkamp ML, Gatt M, Hirahara F, Landau D, Lowry RB, Marengo L, McDonnell R, Mathew TM, Morgan M, Mutchinick OM, Pierini A, Poetzsch S, Ritvanen A, Scarano G, Siffel C, Sipek A, Szabova E, Tagliabue G, Vollset SE, Wertelecki W, Zhuchenko L, Mastroiacovo P: How valid are the rates of Down syndrome internationally? Findings from the International Clearinghouse for Birth Defects Surveillance and Research. Am J Med Genet A 2010; 152A:1670-1680.
5. Epstein CJ, Korenberg JR, Anneren G, Antonarakis SE, Ayme S, Courchesne E, Epstein LB, Fowler A, Groner Y, Huret JL, et al: Protocols to establish genotype-phenotype correlations in Down syndrome. Am J Hum Genet 1991; 49: 207-235.
6. Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S: Chromosome 21 and Down syndrome: from genomics to pathophysiology. Nat Rev Genet 2004; 5: 725-738.
7. Korbel JO, Tirosh-Wagner T, Urban AE, Chen XN, Kasowski M, Dai L, Grubert F, Erdman C, Gao MC, Lange K, Sobel EM, Barlow GM, Aylsworth AS, Carpenter NJ, Clark RD, Cohen MY, Doran E, Falik-Zaccai T, Lewin SO, Lott IT, McGillivray BC, Moeschler JB, Pettenati MJ, Pueschel SM, Rao KW, Shaffer LG, Shohat M, Van Riper AJ, Warburton D, Weissman S, Gerstein MB, Snyder M, Korenberg JR: The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc Natl Acad Sci USA 2009; 106: 12031-12036.
8. Cua CL, Blankenship A, North AL, Hayes J, Nelin LD: Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates. Pediatr Cardiol 2007; 28: 250-254.
9. Hawkins A, Langton-Hewer S, Henderson J, Tulloh RM: Management of pulmonary hypertension in Down syndrome. Eur J Pediatr 2011, E-pub ahead of print.
10. Gearhart JD, Oster-Granite ML, Reeves RH, Coyle JT: Developmental consequences of autosomal aneuploidy in mammals. Dev Genet 1987; 8: 249-265.
11. Gardiner K: Gene-dosage effects in Down syndrome and trisomic mouse models. Genome Biol 2004; 5: 244.
12. Chrast R, Scott HS, Papasavvas MP, Rossier C, Antonarakis ES, Barras C, Davisson MT, Schmidt C, Estivill X, Dierssen M, Pritchard M, Antonarakis SE: The mouse brain transcriptome by SAGE: differences in gene expression between P30 brains of the partial trisomy 16 mouse model of Down syndrome (Ts65Dn) and normals. Genome Res 2000; 10: 2006-2021.
13. Lyle R, Gehrig C, Neergaard-Henrichsen C, Deutsch S, Antonarakis SE: Gene expression from the aneuploid chromosome in a trisomy mouse model of Down syndrome. Genome Res 2004; 14: 1268-1274.
14. Kahlem P, Sultan M, Herwig R, Steinfath M, Balzereit D, Eppens B, Saran NG, Pletcher MT, South ST, Stetten G, Lehrach H, Reeves RH, Yaspo ML: Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of down syndrome. Genome Res 2004; 14: 1258-1267.
15. Amano K, Sago H, Uchikawa C, Suzuki T, Kotliarova SE, Nukina N, Epstein CJ, Yamakawa K: Dosage-dependent over-expression of genes in the trisomic region of Ts1Cje mouse model for Down syndrome. Hum Mol Genet 2004; 13: 1333-1340.
16. Reeves RH, Baxter LL, Richtsmeier JT: Too much of a good thing: mechanisms of gene action in Down syndrome. Trends Genet 2001; 17: 83-88.
17. Korenberg JR: Down syndrome: the crucible for treating genomic imbalance. Genet Med 2009; 11: 617-619.
18. Gardiner K, Herault Y, Lott IT, Antonarakis SE, Reeves RH, Dierssen M: Down syndrome: from understanding the neurobiology to therapy. J Neurosci 2010; 30: 14943-14945.
19. Olson LE, Richtsmeier JT, Leszl J, Reeves RH: A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science 2004; 306: 687-690.
20. Pereira PL, Magnol L, Sahun I, Brault V, Duchon A, Prandini P, Gruart A, Bizot JC, Chadefaux-Vekemans B, Deutsch S, Trovero F, Delgado-Garcia JM, Antonarakis SE, Dierssen M, Herault Y: A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of Down syndrome. Hum Mol Genet 2009; 18: 4756-4769.
21. Roper RJ, Reeves RH: Understanding the basis for Down syndrome phenotypes. PLoS Genet 2006; 2:e50.
22. De Vita S, Canzonetta C, Mulligan C, Delom F, Groet J, Baldo C, Vanes L, Dagna-Bricarelli F, Hoischen A, Veltman J, Fisher EM, Tybulewicz VL, Nizetic D: Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome. Oncogene 2010; 29: 6102-6114.
23. Neri G, Opitz JM: Down syndrome: comments and reflections on the 50th anniversary of Lejeune's discovery. Am J Med Genet A 2009; 149A:2647-2654.
24. Tiano L, Carnevali P, Padella L, Santoro L, Principi F, Bruge F, Carle F, Gesuita R, Gabrielli O, Littarru GP: Effect of Coenzyme Q(10) in mitigating oxidative DNA damage in Down syndrome patients, a double blind randomized controlled trial. Neurobiol Aging 2009, E-pub ahead of print.
25. Gropman AL, Batshaw ML: Epigenetics, copy number variation, and other molecular mechanisms underlying neurodevelopmental disabilities: new insights and diagnostic approaches. J Dev Behav Pediatr 2010; 31: 582-591.
26. Calfa G, Percy AK, Pozzo-Miller L: Experimental models of Rett syndrome based on Mecp2 dysfunction. Exp Biol Med (Maywood) 2011; 236: 3-19.
27. Du Y, Zhang J, Wang H, Yan X, Yang Y, Yang L, Luo X, Chen Y, Duan T, Ma D: Hypomethylated DSCR4 is a placenta-derived epigenetic marker for trisomy 21. Prenat Diagn 2011; 31: 207-214.
28. Im HI, Hollander JA, Bali P, Kenny PJ: MeCP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212. Nat Neurosci 2010; 13: 1120-1127.
29. Wu H, Tao J, Chen PJ, Shahab A, Ge W, Hart RP, Ruan X, Ruan Y, Sun YE: Genome-wide analysis reveals methyl-CpG-binding protein 2-dependent regulation of microRNAs in a mouse model of Rett syndrome. Proc Natl Acad Sci USA 2010; 107: 18161-18166.
30. Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, Elton TS, Hatzigeorgiou AG, Antonarakis SE: Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet 2007; 81: 405-413.
31. Kuhn DE, Nuovo GJ, Martin MM, Malana GE, Pleister AP, Jiang J, Schmittgen TD, Terry AV Jr, Gardiner K, Head E, Feldman DS, Elton TS: Human chromosome 21-derived miRNAs are overexpressed in Down syndrome brains and hearts. Biochem Biophys Res Commun 2008; 370: 473-477.
32. Kuhn DE, Nuovo GJ, Terry AV Jr, Martin MM, Malana GE, Sansom SE, Pleister AP, Beck WD, Head E, Feldman DS, Elton TS: Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains. J Biol Chem 2010; 285: 1529-1543.
33. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
34. Bushati N, Cohen SM: MicroRNA functions. Annu Rev Cell Dev Biol 2007; 23: 175-205.
35. Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W: Stress-induced reversal of microRNA repression and mRNA P-body localization in human cells. Cold Spring Harb Symp Quant Biol 2006; 71: 513-521.
36. Vasudevan S, Tong Y, Steitz JA: Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318: 1931-1934.
37. Chen K, Rajewsky N: The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 2007; 8: 93-103.
38. Li X, Cassidy JJ, Reinke CA, Fischboeck S, Carthew RW: A microRNA imparts robustness against environmental fluctuation during development. Cell 2009; 137: 273-282.
39. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker- Radtke A, McConkey D, Bar-Eli M, Dinney C: miR-200 expression regulates epithelialto- mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009; 15: 5060-5072.
40. Gusev Y: Computational methods for analysis of cellular functions and pathways collectively targeted by differentially expressed microRNA. Methods 2008; 44: 61-72.
41. Tan Y, Zhang B, Wu T, Skogerbo G, Zhu X, Guo X, He S, Chen R: Transcriptional inhibition of Hoxd4 expression by miRNA-10a in human breast cancer cells. BMC Mol Biol 2009; 10: 12.
42. Tsai KW, Kao HW, Chen HC, Chen SJ, Lin WC: Epigenetic control of the expression of a primate-specific microRNA cluster in human cancer cells. Epigenetics 2009; 4: 587-592.
43. Klein ME, Lioy DT, Ma L, Impey S, Mandel G, Goodman RH: Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat Neurosci 2007; 10: 1513-1514.
44. Nomura T, Kimura M, Horii T, Morita S, Soejima H, Kudo S, Hatada I: MeCP2-dependent repression of an imprinted miR-184 released by depolarization. Hum Mol Genet 2008; 17: 1192-1199.
45. Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, Goodman RH, Impey S: A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc Natl Acad Sci USA 2005; 102: 16426-16431.
46. Wu J, Xie X: Comparative sequence analysis reveals an intricate network among REST, CREB and miRNA in mediating neuronal gene expression. Genome Biol 2006; 7:R85.
47. Lugli G, Larson J, Martone ME, Jones Y, Smalheiser NR: Dicer and eIF2c are enriched at postsynaptic densities in adult mouse brain and are modified by neuronal activity in a calpain-dependent manner. J Neurochem 2005; 94: 896-905.
48. Smalheiser NR, Lugli G: MicroRNA regulation of synaptic plasticity. Neuromolecular Med 2009; 11: 133-140.
49. Barbosa AC, Kim MS, Ertunc M, Adachi M, Nelson ED, McAnally J, Richardson JA, Kavalali ET, Monteggia LM, Bassel-Duby R, Olson EN: MEF2C, a transcription factor that facilitates learning and memory by negative regulation of synapse numbers and function. Proc Natl Acad Sci USA 2008; 105: 9391-9396.
50. Josselyn SA, Kida S, Silva AJ: Inducible repression of CREB function disrupts amygdala- dependent memory. Neurobiol Learn Mem 2004; 82: 159-163. Expression of microRNA in Ts65Dn Dev Neurosci 2011;33:451-467 465
51. Bhattacharyya S, Balakathiresan NS, DalgardC, Gutti U, Armistead D, Jozwik C, Srivastava M, Pollard HB, Biswas R: Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin- 8. J Biol Chem 2011; 286: 11604-11615.
52. Pedersen IM, Otero D, Kao E, Miletic AV, Hother C, Ralfkiaer E, Rickert RC, Gronbaek K, David M: Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol Med 2009; 1: 288-295.
53. Voronov SV, Frere SG, Giovedi S, Pollina EA, Borel C, Zhang H, Schmidt C, Akeson EC, Wenk MR, Cimasoni L, Arancio O, Davisson MT, Antonarakis SE, Gardiner K, De Camilli P, Di Paolo G: Synaptojanin 1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down's syndrome. Proc Natl Acad Sci USA 2008; 105: 9415-9420.
54. Soeda Y, Tsuneki H, Muranaka H, Mori N, Hosoh S, Ichihara Y, Kagawa S, Wang X, Toyooka N, Takamura Y, Uwano T, Nishijo H, Wada T, Sasaoka T: The inositol phosphatase SHIP2 negatively regulates insulin/IGFI actions implicated in neuroprotection and memory function in mouse brain. Mol Endocrinol 2010; 24: 1965-1977.
55. Gong LW, De Camilli P: Regulation of postsynaptic AMPA responses by synaptojanin 1. Proc Natl Acad Sci USA 2008; 105: 17561-17566.
56. Herrera F, Chen Q, Fischer WH, Maher P, Schubert DR: Synaptojanin-1 plays a key role in astrogliogenesis: possible relevance for Down's syndrome. Cell Death Differ 2009; 16: 910-920.
57. Ren XR, Hong Y, Feng Z, Yang HM, Mei L, Xiong WC: Tyrosine phosphorylation of netrin receptors in netrin-1 signaling. Neurosignals 2008; 16: 235-245.
58. Gardiner K, Fortna A, Bechtel L, Davisson MT: Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene 2003; 318: 137-147.
59. Akeson EC, Lambert JP, Narayanswami S, Gardiner K, Bechtel LJ, Davisson MT: Ts65Dn - localization of the translocation breakpoint and trisomic gene content in a mouse model for Down syndrome. Cytogenet Cell Genet 2001; 93: 270-276.
60. Chakrabarti L, Galdzicki Z, Haydar TF: Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts- 65Dn mouse model of Down syndrome. J Neurosci 2007; 27: 11483-11495.
61. Chakrabarti L, Best TK, Cramer NP, Carney RS, Isaac JT, Galdzicki Z, Haydar TF: Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nat Neurosci 2010; 13: 927-934.
62. Escorihuela RM, Fernandez-Teruel A, Vallina IF, Baamonde C, Lumbreras MA, Dierssen M, Tobena A, Florez J: A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci Lett 1995; 199: 143-146.
63. Holtzman DM, Santucci D, Kilbridge J, Chua- Couzens J, Fontana DJ, Daniels SE, Johnson RM, Chen K, Sun Y, Carlson E, Alleva E, Epstein CJ, Mobley WC: Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci USA 1996; 93: 13333-13338.
64. Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, Schmidt C, Bronson RT, Davisson MT: A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet 1995; 11: 177-184.
65. Nadel L: Down's syndrome: a genetic disorder in biobehavioral perspective. Genes Brain Behav 2003; 2: 156-166.
66. Pennington BF, Moon J, Edgin J, Stedron J, Nadel L: The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev 2003; 74: 75-93.
67. Siarey RJ, Carlson EJ, Epstein CJ, Balbo A, Rapoport SI, Galdzicki Z: Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology 1999; 38: 1917-1920.
68. Siarey RJ, Stoll J, Rapoport SI, Galdzicki Z: Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down syndrome. Neuropharmacology 1997; 36: 1549-1554.
69. Roizen NJ, Amarose AP: Hematologic abnormalities in children with Down syndrome. Am J Med Genet 1993; 46: 510-512.
70. Kivivuori SM, Rajantie J, Siimes MA: Peripheral blood cell counts in infants with Down's syndrome. Clin Genet 1996; 49: 15-19.
71. Lange B: The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 2000; 110: 512-524.
72. Kirsammer G, Jilani S, Liu H, Davis E, Gurbuxani S, Le Beau MM, Crispino JD: Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood 2008; 111: 767-775.
73. Williams AD, Mjaatvedt CH, Moore CS: Characterization of the cardiac phenotype in neonatal Ts65Dn mice. Dev Dyn 2008; 237: 426-435.
74. Lorenzi H, Duvall N, Cherry SM, Reeves RH, Roper RJ: PCR prescreen for genotyping the Ts65Dn mouse model of Down syndrome. Biotechniques 2010; 48: 35-38.
75. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3:RESEARCH0034.
76. Prophet EB, Mills B, Arrington JB, Sobin LH: Laboratory Methods in Histotechnology. Washington, Armed Forces Institute of Pathology, 1992, vol 178, pp 197-198.
77. Mural RJ, Adams MD, Myers EW, Smith HO, Miklos GL, Wides R, Halpern A, Li PW, Sutton GG, Nadeau J, Salzberg SL, Holt RA, Kodira CD, Lu F, Chen L, Deng Z, Evangelista CC, Gan W, Heiman TJ, Li J, Li Z, Merkulov GV, Milshina NV, Naik AK, Qi R, Shue BC, Wang A, Wang J, Wang X, Yan X, Ye J, Yooseph S, Zhao Q, Zheng L, Zhu SC, Biddick K, Bolanos R, Delcher AL, Dew IM, Fasulo D, Flanigan MJ, Huson DH, Kravitz SA, Miller JR, Mobarry CM, Reinert K, Remington KA, Zhang Q, Zheng XH, Nusskern DR, Lai Z, Lei Y, Zhong W, Yao A, Guan P, Ji RR, Gu Z, Wang ZY, Zhong F, Xiao C, Chiang CC, Yandell M, Wortman JR, Amanatides PG, Hladun SL, Pratts EC, Johnson JE, Dodson KL, Woodford KJ, Evans CA, Gropman B, Rusch DB, Venter E, Wang M, Smith TJ, Houck JT, Tompkins DE, Haynes C, Jacob D, Chin SH, Allen DR, Dahlke CE, Sanders R, Li K, Liu X, Levitsky AA, Majoros WH, Chen Q, Xia AC, Lopez JR, Donnelly MT, Newman MH, Glodek A, Kraft CL, Nodell M, Ali F, An HJ, Baldwin-Pitts D, Beeson KY, Cai S, Carnes M, Carver A, Caulk PM, Center A Chen YH, Cheng ML, Coyne MD, Crowder M, Danaher S, Davenport LB, Desilets R, Dietz SM, Doup L, Dullaghan P, Ferriera S, Fosler CR, Gire HC, Gluecksmann A, Gocayne JD, Gray J, Hart B, Haynes J, Hoover J, Howland T, Ibegwam C, Jalali M, Johns D, Kline L, Ma DS, MacCawley S, Magoon A, Mann F, May D, McIntosh TC, Mehta S, Moy L, Moy MC, Murphy BJ, Murphy SD, Nelson KA, Nuri Z, Parker KA, Prudhomme AC, Puri VN, Qureshi H, Raley JC, Reardon MS, Regier MA, Rogers YH, Romblad DL, Schutz J, Scott JL, Scott R, Sitter CD, Smallwood M, Sprague AC, Stewart E, Strong RV, Suh E, Sylvester K, Thomas R, Tint NN, Tsonis C, Wang G, Williams MS, Williams SM, Windsor SM, Wolfe K, Wu MM, Zaveri J, Chaturvedi K, Gabrielian AE, Ke Z, Sun J, Subramanian G, Venter JC, Pfannkoch CM, Barnstead M, Stephenson LD: A comparison of whole-genome shotgun-derived mouse chromosome 16 and the human genome. Science 2002; 296: 1661-1671.
78. Cammarata G, Augugliaro L, Salemi D, Agueli C, La Rosa M, Dagnino L, Civiletto G, Messana F, Marfia A, Bica MG, Cascio L, Floridia PM, Mineo AM, Russo M, Fabbiano F, Santoro A: Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol 2010; 85: 331-339.
79. Eyholzer M, Schmid S, Schardt JA, Haefliger S, Mueller BU, Pabst T: Complexity of miR- 223 regulation by CEBPA in human AML. Leuk Res 2010; 34: 672-676. Dev Neurosci 2011;33:451-467 Keck-Wherley et al.
80. Navarro F, Lieberman J: Small RNAs guide hematopoietic cell differentiation and function. J Immunol 2010; 184: 5939-5947.
81. Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J: The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol 2010; 84: 1-16.
82. Katayama Y, Tamura T, Becker DP, Tsubokawa T: Calcium-dependent component of massive increase in extracellular potassium during cerebral ischemia as demonstrated by microdialysis in vivo. Brain Res 1991; 567: 57-63.
83. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B, Rigoutsos I: A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006; 126: 1203-1217.
84. Maragkakis M, Alexiou P, Papadopoulos GL, Reczko M, Dalamagas T, Giannopoulos G, Goumas G, Koukis E, Kourtis K, Simossis VA, Sethupathy P, Vergoulis T, Koziris N, Sellis T, Tsanakas P, Hatzigeorgiou AG: Accurate microRNA target prediction correlates with protein repression levels. BMC Bioinformatics 2009; 10: 295.
85. Wang X: miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA 2008; 14: 1012-1017.
86. Friedman RC, Farh KK, Burge CB, Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
87. Siarey RJ, Kline-Burgess A, Cho M, Balbo A, Best TK, Harashima C, Klann E, Galdzicki Z: Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome. J Neurochem 2006; 98: 1266-1277.
88. Shukkur EA, Shimohata A, Akagi T, Yu W, Yamaguchi M, Murayama M, Chui D, Takeuchi T, Amano K, Subramhanya KH, Hashikawa T, Sago H, Epstein CJ, Takashima A, Yamakawa K: Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome. Hum Mol Genet 2006; 15: 2752-2762.
89. Wedgwood S, Black SM: Role of reactive oxygen species in vascular remodeling associated with pulmonary hypertension. Antioxid Redox Signal 2003; 5: 759-769.
90. Tibballs J, Chow CW: Incidence of alveolar capillary dysplasia in severe idiopathic persistent pulmonary hypertension of the newborn. J Paediatr Child Health 2002; 38: 397-400.
91. Patterson D: Molecular genetic analysis of Down syndrome. Hum Genet 2009; 126: 195-214.
92. Galdzicki Z, Siarey RJ: Understanding mental retardation in Down's syndrome using trisomy 16 mouse models. Genes Brain Behav 2003; 2: 167-178.
93. Baek KH, Zaslavsky A, Lynch RC, Britt C, Okada Y, Siarey RJ, Lensch MW, Park IH, Yoon SS, Minami T, Korenberg JR, Folkman J, Daley GQ, Aird WC, Galdzicki Z, Ryeom S: Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 2009; 459: 1126-1130.
94. Xavier AC, Taub JW: Acute leukemia in children with Down syndrome. Haematologica 2010; 95: 1043-1045.
95. Kye MJ, Liu T, Levy SF, Xu NL, Groves BB, Bonneau R, Lao K, Kosik KS: Somatodendritic microRNAs identified by laser capture and multiplex RT-PCR. RNA 2007; 13: 1224-1234.
96. Ahn HJ, Hernandez CM, Levenson JM, Lubin FD, Liou HC, Sweatt JD: c-Rel, an NFkappaB family transcription factor, is required for hippocampal long-term synaptic plasticity and memory formation. Learn Mem 2008; 15: 539-549.
97. Greer PL, Greenberg ME: From synapse to nucleus: calcium-dependent gene transcription in the control of synapse development and function. Neuron 2008; 59: 846-860.
98. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D: Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA 2009; 106: 7113-7118.
99. Vargova K, Curik N, Burda P, Basova P, Kulvait V, Pospisil V, Savvulidi F, Kokavec J, Necas E, Berkova A, Obrtlikova P, Karban J, Mraz M, Pospisilova S, Mayer J, Trneny M, Zavadil J, Stopka T: MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood 2011; 117: 3816-3825.
100. Kluiver J, van den Berg A, de Jong D, Blokzijl T, Harms G, Bouwman E, Jacobs S, Poppema S, Kroesen BJ: Regulation of primicroRNA BIC transcription and processing in Burkitt lymphoma. Oncogene 2007; 26: 3769-3776.
101. Liu DZ, Tian Y, Ander BP, Xu H, Stamova BS, Zhan X, Turner RJ, Jickling G, Sharp FR: Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures. J Cereb Blood Flow Metab 2010; 30: 92-101.
102. Juan AH, Kumar RM, Marx JG, Young RA, Sartorelli V: Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells. Mol Cell 2009; 36: 61-74.
103. Pereira JD, Sansom SN, Smith J, Dobenecker MW, Tarakhovsky A, Livesey FJ: Ezh2, the histone methyltransferase of PRC2, regulates the balance between self-renewal and differentiation in the cerebral cortex. Proc Natl Acad Sci USA 2010; 107: 15957-15962.
104. Szulwach KE, Li X, Smrt RD, Li Y, Luo Y, Lin L, Santistevan NJ, Li W, Zhao X, Jin P: Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J Cell Biol 2010; 189: 127-141.
105. Clark S, Schwalbe J, Stasko MR, YarowskyPJ, Costa AC: Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts- 65Dn mouse model for Down syndrome. Exp Neurol 2006; 200: 256-261.
106. Bianchi P, Ciani E, Contestabile A, Guidi S, Bartesaghi R: Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down syndrome. Brain Pathol 2010; 20: 106-118.
107. Flynt AS, Li N, Thatcher EJ, Solnica-Krezel L, Patton JG: Zebrafish miR-214 modulates Hedgehog signaling to specify muscle cell fate. Nat Genet 2007; 39: 259-263.
108. Roper RJ, Baxter LL, Saran NG, Klinedinst DK, Beachy PA, Reeves RH: Defective cerebellar response to mitogenic Hedgehog signaling in Down [corrected] syndrome mice. Proc Natl Acad Sci USA 2006; 103: 1452-1456.
109. Baxter LL, Moran TH, Richtsmeier JT, Troncoso J, Reeves RH: Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Hum Mol Genet 2000; 9: 195-202.
110. Bianchi P, Ciani E, Guidi S, Trazzi S, Felice D, Grossi G, Fernandez M, Giuliani A, Calza L, Bartesaghi R: Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J Neurosci 2010; 30: 8769-8779.
111. Huehnchen P, Prozorovski T, Klaissle P, Lesemann A, Ingwersen J, Wolf SA, Kupsch A, Aktas O, Steiner B: Modulation of adult hippocampal neurogenesis during myelindirected autoimmune neuroinflammation. Glia 2011; 59: 132-142.
112. Sims JR, Lee SW, Topalkara K, Qiu J, Xu J, Zhou Z, Moskowitz MA: Sonic hedgehog regulates ischemia/hypoxia-induced neural progenitor proliferation. Stroke 2009; 40: 3618-3626.
113. Redell JB, Liu Y, Dash PK: Traumatic brain injury alters expression of hippocampal microRNAs: potential regulators of multiple pathophysiological processes. J Neurosci Res 2009; 87: 1435-1448.
114. Izumi B, Nakasa T, Tanaka N, Nakanishi K, Kamei N, Yamamoto R, Nakamae T, Ohta R, Fujioka Y, Yamasaki K, Ochi M: MicroRNA- 223 expression in neutrophils in the early phase of secondary damage after spinal cord injury. Neurosci Lett 2011; 492: 114-118.
115. Albensi BC, Sullivan PG, Thompson MB, Scheff SW, Mattson MP: Cyclosporin ameliorates traumatic brain-injury-induced alterations of hippocampal synaptic plasticity. Exp Neurol 2000; 162: 385-389. Expression of microRNA in Ts65Dn Dev Neurosci 2011;33:451-467 467
116. Siegel G, Obernosterer G, Fiore R, Oehmen M, Bicker S, Christensen M, Khudayberdiev S, Leuschner PF, Busch CJ, Kane C, Hubel K, Dekker F, Hedberg C, Rengarajan B, Drepper C, Waldmann H, Kauppinen S, Greenberg ME, Draguhn A, Rehmsmeier M, Martinez J, Schratt GM: A functional screen implicates microRNA-138-dependent regulation of the depalmitoylation enzyme APT1 in dendritic spine morphogenesis. Nat Cell Biol 2009; 11: 705-716.
117. Lee HJ, Palkovits M, Young WS 3rd: miR- 7b, a microRNA up-regulated in the hypothalamus after chronic hyperosmolar stimulation, inhibits Fos translation. Proc Natl Acad Sci USA 2006; 103: 15669-15674.
118. Greber-Platzer S, Balcz B, Cairns N, Lubec G: c-fos expression in brains of patients with Down syndrome. J Neural Transm Suppl 1999; 57: 75-85.
119. Malinge S, Izraeli S, Crispino JD: Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 2009; 113: 2619-2628.
120. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM: Reprogramming of miRNA networks in cancer and leukemia. Genome Res 2010; 20: 589-599.
121. Costinean S, Sandhu SK, Pedersen IM, Tili E, Trotta R, Perrotti D, Ciarlariello D, Neviani P, Harb J, Kauffman LR, Shidham A, Croce CM: Src homology 2 domaincontaining inositol-5-phosphatase and CCAAT enhancer-binding protein beta aretargeted by miR-155 in B cells of Emicro- MiR-155 transgenic mice. Blood 2009; 114: 1374-1382.
122. Wang M, Tan LP, Dijkstra MK, van Lom K, Robertus JL, Harms G, Blokzijl T, Kooistra K, van T'veer MB, Rosati S, Visser L, Jongen- Lavrencic M, Kluin PM, van den Berg A: miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol 2008; 215: 13-20.
123. Pulikkan JA, Dengler V, Peramangalam PS, Peer Zada AA, Muller-Tidow C, Bohlander SK, Tenen DG, Behre G: Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood 2010; 115: 1768-1778.
124. Klusmann JH, Li Z, Bohmer K, Maroz A, Koch ML, Emmrich S, Godinho FJ, Orkin SH, Reinhardt D: miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev 2010; 24: 478-490.
125. Hasle H, Clemmensen IH, Mikkelsen M: Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000; 355: 165-169.
126. Chiaretti S, Messina M, Tavolaro S, Zardo G, Elia L, Vitale A, Fatica A, Gorello P, Piciocchi A, Scappucci G, Bozzoni I, Fozza C, Candoni A, Guarini A, Foa R: Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and overexpression of miR-223. Haematologica 2010; 95: 1114-1121.
127. Hussein K, Theophile K, Dralle W, Wiese B, Kreipe H, Bock O: MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia. Platelets 2009; 20: 391-400.
128. Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G, Capogrossi MC, Martelli F: MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 2008; 283: 15878-15883.
129. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT, Giaccia AJ: Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009; 35: 856-867.
130. Yang Q, Rasmussen SA, Friedman JM: Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population- based study. Lancet 2002; 359: 1019-1025.
131. Courboulin A, Paulin R, Giguere NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Cote J, Simard MJ, Bonnet S: Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011; 14: 14.
132. Saran NG, Pletcher MT, Natale JE, Cheng Y, Reeves RH: Global disruption of the cerebellar transcriptome in a Down syndrome mouse model. Hum Mol Genet 2003; 12: 2013-2019.
133. Dauphinot L, Lyle R, Rivals I, Dang MT, Moldrich RX, Golfier G, Ettwiller L, Toyama K, Rossier J, Personnaz L, Antonarakis SE, Epstein CJ, Sinet PM, Potier MC: The cerebellar transcriptome during postnatal development of the Ts1Cje mouse, a segmental trisomy model for Down syndrome. Hum Mol Genet 2005; 14: 373-384.
134. Paz-Miguel JE, Flores R, Sánchez-Velasco P, Ocejo-Vinyals G, Escribano de Diego J, López de Rego J, Leyva-Cobián F: Reactive oxygen intermediates during programmed cell death induced in the thymus of the Ts(1716)65Dn mouse, a murine model for human Down's syndrome. J Immunol 1999; 163: 5399-5410.
135. Strydom A, Dickinson MJ, Shende S, Pratico D, Walker Z: Oxidative stress and cognitive ability in adults with Down syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 76-80.
136. Iannello RC, Crack PJ, de Haan JB, Kola I: Oxidative stress and neural dysfunction in Down syndrome. J Neural Transm Suppl 1999; 57: 257-267.
137. Chakrabarti L, Galdzicki Z, Haydar TF: Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. J Neurosci 2007; 27: 11483-11495.
138. Haydar TF, Nowakowski RS, Yarowsky PJ, Krueger BK: Role of founder cell deficit and delayed neuronogenesis in microencephaly of the trisomy 16 mouse. J Neurosci 2000; 20: 4156-4164.
139. Reynolds LE, Watson AR, Baker M, Jones TA, D'Amico G, Robinson SD, Joffre C, Garrido-Urbani S, Rodriguez-Manzaneque JC, Martino-Echarri E, Aurrand- Lions M, Sheer D, Dagna-Bricarelli F, Nizetic D, McCabe CJ, Turnell AS, Kermorgant S, Imhof BA, Adams R, Fisher EM, Tybulewicz VL, Hart IR, Hodivala-Dilke KM: Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature 2010; 465: 813-817.
140. Guidi S, Ciani E, Bonasoni P, Santini D, Bartesaghi R: Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with Down syndrome. Brain Pathol 2011; 21: 361-373.
141. Olson LE, Roper RJ, Baxter LL, Carlson EJ, Epstein CJ, Reeves RH: Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn exhibit variable severity of cerebellar phenotypes. Dev Dyn 2004; 230: 581-589.
142. Fernandez F, Morishita W, Zuniga E, Nguyen J, Blank M, Malenka RC, Garner CC: Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 2007; 10: 411-413.